This study is testing a new medicine, in healthy adults to assess its safety and understand how it behaves in the body. The purpose of this study is to evaluate the safety, tolerability, and how the body responds to a single dose of NNC0642-1895 in healthy adults. Participant will either get study medicine (NNC0642-1895) or placebo (a treatment that has no active medicine in it). Which treatment a participant receives is decided by chance. NNC0642-1895 is a new medicine that is being tested in humans for the first time and is not currently available for doctors to prescribe. The study will last for about 94 days (approximately 14 weeks).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
148
NNC0642-1895 will be administered intravenously.
Placebo will be administered intravenously.
ICON-Salt Lake City
Salt Lake City, Utah, United States
Number of treatment emergent adverse events (TEAE)
Measured as number of events.
Time frame: From pre-dose (Day 1) to Day 66
AUC0-∞; the area under the NNC0642-1895 serum concentration-time curve from time 0 to infinity after a single dose
Measured as nanomoles per liter hour (nmol/L\*h).
Time frame: From pre-dose (Day 1) to Day 66
Cmax; the observed maximum serum concentration of NNC0642-1895 after a single dose
Measured as nanomoles per liter (nmol/L).
Time frame: From pre-dose (Day 1) to Day 66
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.